GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » Profitability Rank

iCo Therapeutics (iCo Therapeutics) Profitability Rank : 0 (As of Mar. 2021)


View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics Profitability Rank?

iCo Therapeutics has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

iCo Therapeutics's Operating Margin % for the quarter that ended in Mar. 2021 was %. As of today, iCo Therapeutics's Piotroski F-Score is 4.


Competitive Comparison of iCo Therapeutics's Profitability Rank

For the Biotechnology subindustry, iCo Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iCo Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iCo Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where iCo Therapeutics's Profitability Rank falls into.



iCo Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

iCo Therapeutics has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

iCo Therapeutics's Operating Margin % for the quarter that ended in Mar. 2021 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2021 ) / Revenue (Q: Mar. 2021 )
=-0.616 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

iCo Therapeutics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


iCo Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


iCo Therapeutics (iCo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines